

Influenza Vaccine Market Share, Size, Key Players, Industry Overview and Business Opportunities 2022-2027

The Influenza Vaccine Market to reach US\$ 9.1 Billion by 2027, exhibiting a CAGR of 7.9% during 2022-2027.



9.1 Billion by 2027, exhibiting a CAGR of 7.9% during 2022-2027.

Influenza is an infection of the throat, lungs, and nose. Common symptoms include head and body aches, cough, fever, and a stuffy or runny nose. Influenza vaccines or flu shots are biological preparations that protect against and prevent severe infections caused by the influenza virus. The vaccines used for influenza are formulated using three different influenza viruses, including influenza type A and B with H3N2 and H1N1 virus strains. These therapeutics are mainly available in inactivated, adjuvant, live attenuated, and recombinant influenza vaccines. Currently, governments of various nations have mandated immunization against influenza among children aged six months to five.

The rising prevalence of influenza and the fueling awareness regarding influenza vaccines are some of the factors primarily driving the market growth. This is further supported by the steadily increasing geriatric population and surging research and development (R&D) activities across the

globe. In addition to this, governments of various countries are introducing free seasonal influenza vaccination programs for all age groups, which, in turn, is providing a boost to the market growth. In line with this, key market players are actively working to develop new vaccines with better efficacy, which is accelerating the market growth. Other factors, such as growing healthcare expenditure and rising clinical trials, are creating a positive outlook for the market.

DDD DDD: <u>https://www.imarcgroup.com/checkout?id=4206&method=1</u>

Influenza Vaccine Market 2022-2027 Competitive Analysis and Segmentation:

Competitive Landscape with Key Players:

The competitive landscape of the influenza vaccine market has been studied in the report with the detailed profiles of the key players operating in the market.

- Abbott Laboratories
- AstraZeneca plc
- CSL Limited
- Daiichi Sankyo Company Limited
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche AG
- Gamma Vaccines Pty Ltd
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- SINOVAC

Key Market Segmentation:

The report has segmented the influenza vaccine market on the basis of breakup by vaccine type, technology, age group, route of administration and region.

Breakup by Vaccine Type:

- Quadrivalent
- Trivalent

Breakup by Technology:

- Egg-based
- Cell-based

Breakup by Age Group:

- Pediatric
- Adult

Breakup by Route of Administration:

- Injection
- Nasal Spray

Breakup by Region:

- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Turkey, South Africa, Others)

Key Highlights of the Report:

- Market Performance (2016-2021)
- Market Outlook (2022-2027)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

000000 0000 0000000 00000000:

Us Generic Injectable Market

Us Generic Drug Market

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing highquality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Elena Anderson IMARC Services Private Limited +1 631-791-1145 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/601353786

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 Newsmatics Inc. All Right Reserved.